The Big Health Care Conundrum: How To Sustainably Unlock The Value Of Diagnostics
Novo Holdings Panel Asks Diagnostics Industry Leaders How To Keep The Focus On Testing Post-Pandemic
With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.
You may also be interested in...
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.
Maintaining the positive changes that health care delivery underwent at the height of COVID-19 has been the talk of the health care industries, but will commercial organizations retain their enthusiasm once the pressures of the pandemic abate?
It is election month in Germany, and the medtech industry has been busy drawing up what it wants from the inevitable post-poll coalition agreement. But all-eclipsing still are the problems that the EU MDR is causing.